Karyopharm Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) is a commercial-stage pharmaceutical company pioneering the science of nuclear export inhibition. The company discovers, develops, and commercializes novel, small-molecule Selective Inhibitor of Nuclear Export (SINE) compounds that target exportin 1 (XPO1), a critical nuclear export protein. Karyopharm's lead commercial asset is XPOVIO (selinexor), which is marketed in the United States in combination with bortezomib and dexamethasone for adult patients with multiple myeloma who have received at least one prior therapy, and as a monotherapy for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Globally, selinexor is approved under the brand names XPOVIO or NEXPOVIO in more than 50 countries and territories through strategic international partnerships.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Implementation of a workforce reduction of approximately 20% of its staff to carefully manage operating expenses and optimize resource allocation.
Expected impact: Aims to reduce cash burn and extend the operational runway to support key clinical milestones.
Focusing resources on advancing lead clinical programs, specifically the Phase 3 SENTRY trial in myelofibrosis and the Phase 3 XPORT-EC-042 trial in endometrial cancer.
Expected impact: Redefine standard of care in myelofibrosis and endometrial cancer, driving long-term franchise expansion.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Menarini is responsible for the commercialization of NEXPOVIO (selinexor) in Europe, the UK, and other international territories, driving royalty and milestone revenues.
Terms: Includes milestone payments and tiered double-digit royalties on net sales.
Antengene is responsible for the development and commercialization of selinexor, eltanexor, and KPT-9274 in the Asia-Pacific region, including China.
Terms: Includes milestone payments and royalties on net sales.
FORUS manages the commercialization and distribution of XPOVIO in Canada.
Terms: Not specified
Global collaboration to develop FoundationOne®CDx as a companion diagnostic to identify patients with TP53 wild-type tumors for the Phase 3 XPORT-EC-042 endometrial cancer trial.
Terms: Not specified